Assessing the roles of EGFR gene copy number, protein expression and mutation in predicting outcomes in non-small-cell lung cancer after treatment with EGFR inhibitors.

作者: Nathan A Pennell , Lecia V Sequist

DOI: 10.2217/17520363.1.1.203

关键词: GefitinibOncologyNon small cellCopy-number variationMedicineBioinformaticsLung cancerProtein expressionEGFR inhibitorsInternal medicineEpidermal growth factor receptorMutation

摘要: Evaluation of: Hirsch FR, Varella-Garcia M, Bunn PA Jr et al.: Molecular predictors of outcome with gefitinib in a Phase III placebo-controlled study advanced non-small-cell lung cancer. J. Clin. Oncol. 24(31), 5034–5042 (2006) [1]. In this article, we critically evaluate recent publication that assessed molecular clinical benefit from treatment gefitinib, small-molecule inhibitor the epidermal growth factor receptor (EGFR), patients EGFR inhibitors, such as have previously been shown to preferentially distinct subgroups cancer patients, and strategies prospectively identify these are under active investigation. study, authors analyzed tissue randomized trial examine association after protein expression, gene copy number, mutations other potential predictive markers. The ...

参考文章(27)
Jim R Woodburn, Susan E Ashton, Simon P Guy, Keith H Gibson, Brenda J Curry, Andrew J Barker, Alan E Wakeling, ZD1839 (Iressa): an orally active inhibitor of epidermal growth factor signaling with potential for cancer therapy. Cancer Research. ,vol. 62, pp. 5749- 5754 ,(2002)
V. Rusch, Ethan Dmitrovsky, C. Cordon-Cardo, S. Hoda, M. Zaman, Jonathan M Kurie, J. Mcintosh, J. Baselga, J. Orazem, Differential expression of the epidermal growth factor receptor and its ligands in primary non-small cell lung cancers and adjacent benign lung Cancer Research. ,vol. 53, pp. 2379- 2385 ,(1993)
Ming-Sound Tsao, Akira Sakurada, Jean-Claude Cutz, Chang-Qi Zhu, Suzanne Kamel-Reid, Jeremy Squire, Ian Lorimer, Tong Zhang, Ni Liu, Manijeh Daneshmand, Paula Marrano, Gilda da Cunha Santos, Alain Lagarde, Frank Richardson, Lesley Seymour, Marlo Whitehead, Keyue Ding, Joseph Pater, Frances A. Shepherd, Erlotinib in lung cancer - molecular and clinical predictors of outcome. The New England Journal of Medicine. ,vol. 353, pp. 133- 144 ,(2005) , 10.1056/NEJMOA050736
Federico Cappuzzo, Fred R. Hirsch, Elisa Rossi, Stefania Bartolini, Giovanni L. Ceresoli, Lynne Bemis, Jerry Haney, Samir Witta, Kathleen Danenberg, Irene Domenichini, Vienna Ludovini, Elisabetta Magrini, Vanesa Gregorc, Claudio Doglioni, Angelo Sidoni, Maurizio Tonato, Wilbur A. Franklin, Lucio Crino, Paul A. Bunn, Marileila Varella-Garcia, Epidermal Growth Factor Receptor Gene and Protein and Gefitinib Sensitivity in Non–Small-Cell Lung Cancer Journal of the National Cancer Institute. ,vol. 97, pp. 643- 655 ,(2005) , 10.1093/JNCI/DJI112
Howard L. West, Wilbur A. Franklin, Jason McCoy, Paul H. Gumerlock, Ralph Vance, Derick H.M. Lau, Kari Chansky, John J. Crowley, David R. Gandara, Gefitinib therapy in advanced bronchioloalveolar carcinoma : Southwest oncology group study S0126 Journal of Clinical Oncology. ,vol. 24, pp. 1807- 1813 ,(2006) , 10.1200/JCO.2005.04.9890
Lecia V. Sequist, Daphne W. Bell, Thomas J. Lynch, Daniel A. Haber, Molecular Predictors of Response to Epidermal Growth Factor Receptor Antagonists in Non–Small-Cell Lung Cancer Journal of Clinical Oncology. ,vol. 25, pp. 587- 595 ,(2007) , 10.1200/JCO.2006.07.3585
Raffaella Sordella, Daphne W Bell, Daniel A Haber, Jeffrey Settleman, Gefitinib-Sensitizing EGFR Mutations in Lung Cancer Activate Anti-Apoptotic Pathways Science. ,vol. 305, pp. 1163- 1167 ,(2004) , 10.1126/SCIENCE.1101637
Thomas J. Lynch, Daphne W. Bell, Raffaella Sordella, Sarada Gurubhagavatula, Ross A. Okimoto, Brian W. Brannigan, Patricia L. Harris, Sara M. Haserlat, Jeffrey G. Supko, Frank G. Haluska, David N. Louis, David C. Christiani, Jeff Settleman, Daniel A. Haber, Activating mutations in the epidermal growth factor receptor underlying responsiveness of non-small-cell lung cancer to gefitinib The New England Journal of Medicine. ,vol. 350, pp. 2129- 2139 ,(2004) , 10.1056/NEJMOA040938
Román Pérez-Soler, Abraham Chachoua, Lisa A. Hammond, Eric K. Rowinsky, Mark Huberman, Daniel Karp, James Rigas, Gary M. Clark, Pedro Santabárbara, Philip Bonomi, Determinants of Tumor Response and Survival With Erlotinib in Patients With Non—Small-Cell Lung Cancer Journal of Clinical Oncology. ,vol. 22, pp. 3238- 3247 ,(2004) , 10.1200/JCO.2004.11.057
Akira Inoue, Takuji Suzuki, Tatsuro Fukuhara, Makoto Maemondo, Yuichiro Kimura, Naoto Morikawa, Hiroshi Watanabe, Yasuo Saijo, Toshihiro Nukiwa, Prospective phase II study of gefitinib for chemotherapy-naive patients with advanced non-small-cell lung cancer with epidermal growth factor receptor gene mutations. Journal of Clinical Oncology. ,vol. 24, pp. 3340- 3346 ,(2006) , 10.1200/JCO.2005.05.4692